Regulus Therapeutics Inc (NASDAQ:RGLS)
During the Trading Day
| 9.99 |  +0.09 / +0.91% |
Data as of 4:00pm ET | Day’s Change |
During After-Hours Switch to standard view »
| 9.99 |  0.00 / 0.00% |
Volume: 2.9K |
Latest RGLS News | Press Releases
| 3 Stocks to Get on Your Watchlist Jun 05 / MotleyFool.com |
Today’s Trading
| Previous close | 9.90 |
| Today’s open | 9.93 |
| Day’s range | 9.89 - 10.05 |
| Volume | 189,612 |
| Average volume (3 months) | 78,281 |
| Market cap | $356.5M |
| Dividend yield | -- |
Data as of 4:00pm ET, 06/19/2013
Growth & Valuation
| Earnings growth (last year) | -872.48% |
| Earnings growth (this year) | +72.36% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | -7.90% |
| P/E ratio | NM |
| Price/Sales | 4.07 |
| Price/Book | 5.71 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| ACRXAcelRx Pharmaceutica... | -0.26 | -2.71% |
| RPRXRepros Therapeutics ... | +0.01 | +0.05% |
| LCILannett Company Inc | -0.47 | -3.88% |
| FURXFuriex Pharmaceutica... | -1.30 | -3.52% |
Data as of 4:00pm ET, 06/19/2013
Financials
| Next reporting date | August 28, 2013 |
| EPS forecast (this quarter) | -$0.13 |
| Annual revenue (last year) | $12.7M |
| Annual profit (last year) | -$17.4M |
| Net profit margin | -137.07% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Other |
President, Chief Executive Officer & Director Kleanthis G. Xanthopoulos, PhD |
Chief Operating Officer & Executive VP-Finance Garry E. Menzel, PhD, MBA |
Corporate headquarters San Diego, California |
Forecasts
